Anticorps Recombinant de lapin anti-Phospho-Myosin Light Chain 2 (Thr18/Ser19)

Phospho-Myosin Light Chain 2 (Thr18/Ser19) Recombinant Antibody for WB, Indirect ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, souris

Applications

WB, Indirect ELISA

Conjugaison

Non conjugué

CloneNo.

1G10

N° de cat : 82717-1-PBS

Synonymes

MYL12A, MYL12B, P MYL12A, P MYL12B, p MYL9



Informations sur le produit

82717-1-PBS cible Phospho-Myosin Light Chain 2 (Thr18/Ser19) dans les applications de WB, Indirect ELISA et montre une réactivité avec des échantillons Humain, souris

Réactivité Humain, souris
Hôte / Isotype Lapin / IgG
Clonalité Recombinant
Type Anticorps
Immunogène Peptide
Nom complet myosin, light chain 9, regulatory
Masse moléculaire calculée 20 kDa
Poids moléculaire observé19-20 kDa
Numéro d’acquisition GenBankBC002648
Symbole du gène MYL9
Identification du gène (NCBI) 10398
Conjugaison Non conjugué
Forme Liquide
Méthode de purification Purification par protéine A
Tampon de stockage PBS only
Conditions de stockageStore at -80°C. 20ul contiennent 0,1% de BSA.

Informations générales

Myosin II is an actin-binding protein composed of MHC (myosin heavy chain), MLCs/MRLCs (myosin regulatory light chains) and ELCs (essential light chains). The Myosin Light Chains are divided into basic MLC (MLC I) and regulatory MLC (MLC II or Myosin Regulatory Light Chain, MRLC). MRLC can be classified into two major types: : class I MRLC found in muscles (MLC1, MLC2, MLC3, MYL4, MYL5, MYL6, MYL7, etc), and class II MRLCs present in non-muscle cells (such as MYL9, MYL12A, MYL12B). Phosphorylation of myosin II regulatory light chain (MRLC) is important for cell motility and cytokinesis in nonmuscle cells. Phosphorylation of MRLC at Ser19 (1P-MRLC) enhances myosin II activity, which is further enhanced by MRLC diphosphorylation at Thr18/Ser19 (2P-MRLC) in vitro .PMID: 23951055,PMID: 21126233
This antibody can recognize the phosphorylation of three highly homologous Myosin-regulated light chains: MYL12A, MYL12B and MYL9.

{{ptg:RelatedPrimaryAntibodies}}